ES2606636T3 - Composición que comprende un antagomir encapsulado - Google Patents
Composición que comprende un antagomir encapsulado Download PDFInfo
- Publication number
- ES2606636T3 ES2606636T3 ES13305082.3T ES13305082T ES2606636T3 ES 2606636 T3 ES2606636 T3 ES 2606636T3 ES 13305082 T ES13305082 T ES 13305082T ES 2606636 T3 ES2606636 T3 ES 2606636T3
- Authority
- ES
- Spain
- Prior art keywords
- microspheres
- composition
- mir
- inhibitor
- antagomir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 239000004005 microsphere Substances 0.000 claims abstract description 136
- 239000002679 microRNA Substances 0.000 claims abstract description 80
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 55
- 108091034121 miR-92a stem-loop Proteins 0.000 claims abstract description 55
- 108091041519 miR-92a-3 stem-loop Proteins 0.000 claims abstract description 54
- 239000003112 inhibitor Substances 0.000 claims abstract description 53
- 108091070501 miRNA Proteins 0.000 claims abstract description 38
- 239000000074 antisense oligonucleotide Substances 0.000 claims abstract description 31
- 238000012230 antisense oligonucleotides Methods 0.000 claims abstract description 31
- 230000000295 complement effect Effects 0.000 claims abstract description 30
- 230000033115 angiogenesis Effects 0.000 claims abstract description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 64
- 239000002773 nucleotide Substances 0.000 claims description 60
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 27
- 229920000642 polymer Polymers 0.000 claims description 27
- 208000033774 Ventricular Remodeling Diseases 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 14
- 229920000249 biocompatible polymer Polymers 0.000 claims description 12
- 208000010125 myocardial infarction Diseases 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 10
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 10
- 229920002988 biodegradable polymer Polymers 0.000 claims description 9
- 230000004048 modification Effects 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 5
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 4
- 108091028664 Ribonucleotide Proteins 0.000 claims description 3
- 230000037429 base substitution Effects 0.000 claims description 3
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 3
- 239000002336 ribonucleotide Substances 0.000 claims description 3
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 108700011259 MicroRNAs Proteins 0.000 description 58
- 210000001519 tissue Anatomy 0.000 description 32
- 229940122938 MicroRNA inhibitor Drugs 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 239000000839 emulsion Substances 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 230000002411 adverse Effects 0.000 description 15
- 150000007523 nucleic acids Chemical group 0.000 description 14
- 230000000302 ischemic effect Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 239000008213 purified water Substances 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000002243 precursor Substances 0.000 description 11
- 238000007634 remodeling Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
- 206010003119 arrhythmia Diseases 0.000 description 10
- 210000004165 myocardium Anatomy 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 206010061216 Infarction Diseases 0.000 description 9
- 230000006793 arrhythmia Effects 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000282898 Sus scrofa Species 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000002035 prolonged effect Effects 0.000 description 8
- 230000000717 retained effect Effects 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 241000282887 Suidae Species 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 230000002861 ventricular Effects 0.000 description 7
- 108091093037 Peptide nucleic acid Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000011859 microparticle Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000010410 reperfusion Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 208000012661 Dyskinesia Diseases 0.000 description 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 5
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- -1 methyleneimino Chemical group 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 4
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 4
- 206010029113 Neovascularisation Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108091074057 miR-16-1 stem-loop Proteins 0.000 description 4
- 108091056204 miR-16-2 stem-loop Proteins 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 206010014513 Embolism arterial Diseases 0.000 description 3
- 108091030146 MiRBase Proteins 0.000 description 3
- 239000004721 Polyphenylene oxide Substances 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 108091031326 miR-15b stem-loop Proteins 0.000 description 3
- 108091091751 miR-17 stem-loop Proteins 0.000 description 3
- 108091049679 miR-20a stem-loop Proteins 0.000 description 3
- 108091039792 miR-20b stem-loop Proteins 0.000 description 3
- 108091029119 miR-34a stem-loop Proteins 0.000 description 3
- 108091084018 miR-34b stem-loop Proteins 0.000 description 3
- 108091090583 miR-34c stem-loop Proteins 0.000 description 3
- 108091047175 miR-374a stem-loop Proteins 0.000 description 3
- 108091056144 miR-374c stem-loop Proteins 0.000 description 3
- 108091080309 miR-483 stem-loop Proteins 0.000 description 3
- 108091033331 miR-503 stem-loop Proteins 0.000 description 3
- 108091028159 miR-92a-1 stem-loop Proteins 0.000 description 3
- 108091025616 miR-92a-2 stem-loop Proteins 0.000 description 3
- 108091038507 miR-92b stem-loop Proteins 0.000 description 3
- 108091007426 microRNA precursor Proteins 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 108091027963 non-coding RNA Proteins 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 229920000570 polyether Polymers 0.000 description 3
- 108091007428 primary miRNA Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 206010040738 Sinus arrest Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 108091037340 miR-15a stem-loop Proteins 0.000 description 2
- 108091069947 miR-15a-1 stem-loop Proteins 0.000 description 2
- 108091048857 miR-24-1 stem-loop Proteins 0.000 description 2
- 108091047483 miR-24-2 stem-loop Proteins 0.000 description 2
- 108091084066 miR-34c-2 stem-loop Proteins 0.000 description 2
- 108091048101 miR-374b stem-loop Proteins 0.000 description 2
- 108091081444 miR-503-1 stem-loop Proteins 0.000 description 2
- 108091023262 miR-503-2 stem-loop Proteins 0.000 description 2
- 108091081014 miR-92b-1 stem-loop Proteins 0.000 description 2
- 108091032846 miR-92b-2 stem loop Proteins 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002357 osmotic agent Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000001023 pro-angiogenic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 201000011531 vascular cancer Diseases 0.000 description 2
- 206010055031 vascular neoplasm Diseases 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- WROTXLSEMHAZEA-UHFFFAOYSA-N 4-diaminophosphoryloxymorpholine Chemical compound NP(N)(=O)ON1CCOCC1 WROTXLSEMHAZEA-UHFFFAOYSA-N 0.000 description 1
- 241000256182 Anopheles gambiae Species 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000251571 Ciona intestinalis Species 0.000 description 1
- 241000500138 Ciona savignyi Species 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 241000255313 Drosophila pseudoobscura Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029470 Nodal rhythm Diseases 0.000 description 1
- 241001482072 Oikopleura dioica Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 229940076189 RNA modulator Drugs 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010045168 Tumour embolism Diseases 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 241000269457 Xenopus tropicalis Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 230000003126 arrythmogenic effect Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000009091 contractile dysfunction Effects 0.000 description 1
- 230000035598 contractile recovery Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000142 dyskinetic effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- IDBOAVAEGRJRIZ-UHFFFAOYSA-N methylidenehydrazine Chemical compound NN=C IDBOAVAEGRJRIZ-UHFFFAOYSA-N 0.000 description 1
- 108091074118 miR-15a-2 stem-loop Proteins 0.000 description 1
- 108091027943 miR-16 stem-loop Proteins 0.000 description 1
- 108091044046 miR-17-1 stem-loop Proteins 0.000 description 1
- 108091069239 miR-17-2 stem-loop Proteins 0.000 description 1
- 108091065423 miR-17-3 stem-loop Proteins 0.000 description 1
- 108091030817 miR-20a-1 stem-loop Proteins 0.000 description 1
- 108091086627 miR-20a-2 stem-loop Proteins 0.000 description 1
- 108091069790 miR-20a-3 stem-loop Proteins 0.000 description 1
- 108091055878 miR-20b-1 stem-loop Proteins 0.000 description 1
- 108091027746 miR-20b-2 stem-loop Proteins 0.000 description 1
- 108091040342 miR-34a-1 stem-loop Proteins 0.000 description 1
- 108091035608 miR-34a-2 stem-loop Proteins 0.000 description 1
- 108091079013 miR-34b Proteins 0.000 description 1
- 108091063470 miR-34b-1 stem-loop Proteins 0.000 description 1
- 108091049916 miR-34b-2 stem-loop Proteins 0.000 description 1
- 108091057222 miR-34b-3 stem-loop Proteins 0.000 description 1
- 108091092639 miR-34b-4 stem-loop Proteins 0.000 description 1
- 108091082133 miR-34c-1 stem-loop Proteins 0.000 description 1
- 108091041286 miR-374 stem-loop Proteins 0.000 description 1
- 108091049973 miR-92a-4 stem-loop Proteins 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000117 poly(dioxanone) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000002186 septum of brain Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13305082.3A EP2759595B1 (en) | 2013-01-24 | 2013-01-24 | Composition comprising an encapsulated antagomir |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2606636T3 true ES2606636T3 (es) | 2017-03-24 |
Family
ID=47683670
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13305082.3T Active ES2606636T3 (es) | 2013-01-24 | 2013-01-24 | Composición que comprende un antagomir encapsulado |
| ES14706098.2T Active ES2688160T3 (es) | 2013-01-24 | 2014-01-23 | Composición que comprende un antagomir encapsulado |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14706098.2T Active ES2688160T3 (es) | 2013-01-24 | 2014-01-23 | Composición que comprende un antagomir encapsulado |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150352055A1 (enExample) |
| EP (2) | EP2759595B1 (enExample) |
| JP (1) | JP2016506923A (enExample) |
| KR (1) | KR20160018451A (enExample) |
| CN (1) | CN105229151A (enExample) |
| AU (1) | AU2014208419A1 (enExample) |
| BR (1) | BR112015017650A2 (enExample) |
| CA (1) | CA2898958A1 (enExample) |
| ES (2) | ES2606636T3 (enExample) |
| HK (1) | HK1219753A1 (enExample) |
| HU (1) | HUE032125T2 (enExample) |
| MX (1) | MX2015009323A (enExample) |
| PL (1) | PL2759595T3 (enExample) |
| RU (1) | RU2668794C2 (enExample) |
| WO (1) | WO2014115103A1 (enExample) |
| ZA (1) | ZA201505602B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6208228B2 (ja) | 2012-06-21 | 2017-10-04 | ミラゲン セラピューティクス， インコーポレイテッド | ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤 |
| EP3247716A4 (en) * | 2015-01-20 | 2018-10-17 | Miragen Therapeutics, Inc. | Mir-92 inhibitors and uses thereof |
| WO2018183127A1 (en) * | 2017-03-25 | 2018-10-04 | MiRagen Therapeutics, Inc. | Mir-92 inhibitors for treatment of heart failure |
| CN113490488A (zh) * | 2019-03-14 | 2021-10-08 | M技术株式会社 | Plga微粒子、其缓释制剂以及其制造方法 |
| CN110484537B (zh) * | 2019-09-02 | 2021-07-27 | 中国水产科学研究院淡水渔业研究中心 | 一种miR-92促进剂及其注射剂的制备方法和应用 |
| CN110804659B (zh) * | 2019-10-23 | 2023-02-03 | 华南农业大学 | 一种血清外泌体ssc-miR-92b-3p作为母猪早期妊娠诊断分子标志物的应用 |
| CN110917359A (zh) * | 2019-11-21 | 2020-03-27 | 武汉理工大学 | 离子键自组装制备PEG-P（Asp-AP）-ANTAGOMIR-RNA微球 |
| WO2021251526A1 (ko) * | 2020-06-11 | 2021-12-16 | 주식회사 프로스테믹스 | 신규한 mirna 유사체 및 이의 용도 |
| CN111729088B (zh) * | 2020-08-21 | 2020-12-15 | 江苏申基生物科技有限公司 | 一种微小核糖核酸miR-34a偶联探针及其制备方法 |
| WO2025050037A1 (en) * | 2023-08-31 | 2025-03-06 | The Regents Of The University Of Colorado, A Body Corporate | Microrna-15b antagomir and cerium oxide nanoparticles, and uses of same for treatment of intrauterine growth restriction |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8383158B2 (en) * | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
| EP1648914A4 (en) * | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| US8288356B2 (en) * | 2007-10-04 | 2012-10-16 | Santaris Pharma A/S | MicroRNAs |
| DE102007052114B4 (de) * | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
| GB0814302D0 (en) * | 2008-08-05 | 2008-10-01 | Coretherapix Slu | Compounds and methods |
| CA2763156A1 (en) * | 2009-05-20 | 2010-11-25 | Board Of Regents, The University Of Texas System | Identification of micro-rnas involved in post-myocardial infarction remodeling and heart failure |
-
2013
- 2013-01-24 EP EP13305082.3A patent/EP2759595B1/en not_active Not-in-force
- 2013-01-24 ES ES13305082.3T patent/ES2606636T3/es active Active
- 2013-01-24 PL PL13305082T patent/PL2759595T3/pl unknown
- 2013-01-24 HU HUE13305082A patent/HUE032125T2/en unknown
-
2014
- 2014-01-23 AU AU2014208419A patent/AU2014208419A1/en not_active Abandoned
- 2014-01-23 CA CA2898958A patent/CA2898958A1/en not_active Abandoned
- 2014-01-23 RU RU2015134770A patent/RU2668794C2/ru not_active IP Right Cessation
- 2014-01-23 ES ES14706098.2T patent/ES2688160T3/es active Active
- 2014-01-23 EP EP14706098.2A patent/EP2948551B1/en not_active Not-in-force
- 2014-01-23 KR KR1020157022914A patent/KR20160018451A/ko not_active Withdrawn
- 2014-01-23 CN CN201480017728.3A patent/CN105229151A/zh active Pending
- 2014-01-23 HK HK16107653.5A patent/HK1219753A1/zh unknown
- 2014-01-23 WO PCT/IB2014/058500 patent/WO2014115103A1/en not_active Ceased
- 2014-01-23 MX MX2015009323A patent/MX2015009323A/es unknown
- 2014-01-23 BR BR112015017650A patent/BR112015017650A2/pt not_active IP Right Cessation
- 2014-01-23 US US14/763,181 patent/US20150352055A1/en not_active Abandoned
- 2014-01-23 JP JP2015554285A patent/JP2016506923A/ja active Pending
-
2015
- 2015-08-04 ZA ZA2015/05602A patent/ZA201505602B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2759595T3 (pl) | 2017-09-29 |
| KR20160018451A (ko) | 2016-02-17 |
| EP2948551A1 (en) | 2015-12-02 |
| MX2015009323A (es) | 2016-04-04 |
| CN105229151A (zh) | 2016-01-06 |
| BR112015017650A2 (pt) | 2017-11-21 |
| HK1219753A1 (zh) | 2017-04-13 |
| ZA201505602B (en) | 2017-05-31 |
| EP2759595A1 (en) | 2014-07-30 |
| WO2014115103A1 (en) | 2014-07-31 |
| US20150352055A1 (en) | 2015-12-10 |
| HUE032125T2 (en) | 2017-08-28 |
| JP2016506923A (ja) | 2016-03-07 |
| RU2015134770A (ru) | 2017-03-03 |
| RU2668794C2 (ru) | 2018-10-02 |
| EP2759595B1 (en) | 2016-09-14 |
| ES2688160T3 (es) | 2018-10-31 |
| AU2014208419A1 (en) | 2015-08-13 |
| EP2948551B1 (en) | 2018-05-02 |
| CA2898958A1 (en) | 2014-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2606636T3 (es) | Composición que comprende un antagomir encapsulado | |
| JP5457414B2 (ja) | オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用 | |
| JP2011256204A5 (enExample) | ||
| JP2020186249A (ja) | 心疾患の処置のための組成物及び方法 | |
| Bheri et al. | Nanoparticle–hydrogel system for post-myocardial infarction delivery of microRNA | |
| EP2436399B1 (en) | Polymeric nano-particles for siRNA delivery using charge interaction and covalent bonding | |
| JP2015525081A5 (enExample) | ||
| Philippen et al. | Antisense MicroRNA therapeutics in cardiovascular disease: quo vadis? | |
| KR102246814B1 (ko) | 치료용 올리고뉴클레오타이드 | |
| Asakiya et al. | Current progress of miRNA-derivative nucleotide drugs: Modifications, delivery systems, applications | |
| ES3001019T3 (es) | Inhibidores del MICRO-RNA 22 | |
| JP2010503640A5 (enExample) | ||
| EP3329004A1 (en) | Therapeutic oligonucleotides | |
| Wang et al. | MicroRNA delivery based on nanoparticles of cardiovascular diseases | |
| US20240417734A1 (en) | Methods for Treating Glioblastoma by Targeting Oncomirs | |
| WO2015133637A1 (ja) | マイクロｒｎａ封入ナノ粒子及びその医薬用途 | |
| EP4634386A1 (en) | Antisense oligonucleotide analogs of mir-29 and uses thereof | |
| CN113811313A (zh) | 食管狭窄抑制剂 | |
| CN107921075B (zh) | 用于治疗肿瘤的细小病毒制剂 | |
| KR101809375B1 (ko) | Ｓｒｃ 키나제 억제제를 포함하는 백반증 개선 또는 백모 치료용 약학적 조성물 | |
| US20250161398A1 (en) | Design and development of a novel messenger rna therapeutic to treat atherosclerosis | |
| CN110787147A (zh) | 一种可用于乳腺癌等肿瘤的dna纳米控释递药分子及其应用 | |
| Usa et al. | Renal Delivery of Anti-microRNA Oligonucleotides in Rats | |
| BR112018001782B1 (pt) | Oligonucleotídeo para uso no tratamento e/ou prevenção de uma doença que compreende o alongamento alternativo dos telômeros, oligonucleotídeo para uso no tratamento e/ou prevenção de uma condição não cancerosa associada à disfunção do telômero e composição farmacêutica |